Home › Funds › BEACON INVESTMENT ADVISORY SERVICES, INC. › VRTX
BEACON INVESTMENT ADVISORY SERVICES, INC. position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
BEACON INVESTMENT ADVISORY SERVICES, INC. reported holding 47,986 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.1M, representing 0.95% of its reported portfolio and ranking #32 among its reported holdings. BEACON INVESTMENT ADVISORY SERVICES, INC. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How BEACON INVESTMENT ADVISORY SERVICES, INC.'s VRTX position evolved
BEACON INVESTMENT ADVISORY SERVICES, INC. first disclosed a stake in VRTX in Q3 2023 at 76,241 shares (US$26.5M). The position peaked in Q1 2025 at 77,901 shares, worth US$37.8M. Across 13 filings, BEACON INVESTMENT ADVISORY SERVICES, INC. increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 47,986 shares valued at US$25.1M — a reduction of -5,394 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 76.24K | $26.51M | New |
| Q4 2023 | 77.92K | $31.70M | Add |
| Q1 2024 | 77.72K | $32.49M | Hold |
| Q2 2024 | 79.23K | $37.14M | Add |
| Q3 2024 | 79.17K | $36.82M | Hold |
| Q4 2024 | 78.82K | $31.74M | Hold |
| Q1 2025 | 77.90K | $37.77M | Reduce |
| Q2 2025 | 77.03K | $34.29M | Reduce |
| Q3 2025 | 76.14K | $29.82M | Reduce |
| Q4 2025 | 74.09K | $33.59M | Reduce |
| Q1 2026 | 56.10K | $25.05M | Reduce |
| Q2 2026 | 53.38K | $26.52M | Reduce |
| Q3 2026 | 47.99K | $25.09M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on BEACON INVESTMENT ADVISORY SERVICES, INC.
FAQ
How long has BEACON INVESTMENT ADVISORY SERVICES, INC. held VRTX?
BEACON INVESTMENT ADVISORY SERVICES, INC. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is BEACON INVESTMENT ADVISORY SERVICES, INC.'s current position in VRTX?
As of Q3 2026, BEACON INVESTMENT ADVISORY SERVICES, INC. holds 47.99K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $25.09M, representing 0.95% of its reported portfolio and ranking #32.
Has BEACON INVESTMENT ADVISORY SERVICES, INC. been buying or selling VRTX?
In the latest 13F filing (Q3 2026), BEACON INVESTMENT ADVISORY SERVICES, INC. reduced its position in VRTX. The position peaked in Q1 2025 at 77.90K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.